News Releases

The new formulation targets internal and external parasites, expanding the BRAVECTO® portfolio Rahway, NJ, – November 26, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Commission has granted the marketing authorization for BRAVECTO® TriUNO, a new formulation of BRAVECTO (fluralaner) for dogs that targets […]

Read more

BRAVECTO eliminated kennel infestations of brown dog ticks (Rhipicephalus sanguineus sensu lato) External imidacloprid/flumethrin collar treatments failed to eliminate all ticks from kennels RAHWAY, N.J., March 15, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the publication of a recent study demonstrating the efficacy of […]

Read more

BRAVECTO rapidly and consistently kills Ixodes scapularis ticks, a vector of the pathogen responsible for Lyme Disease, as compared to Simparica TRIO® RAHWAY, N.J., February 2, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the publication of a recent study demonstrating BRAVECTO® (fluralaner) Chews for […]

Read more